Related Articles
EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells
Amplification of mutant <em>KRAS</em><sup>G12D</sup> in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report
Effect of KRAS and NRAS mutations on the prognosis of patients with synchronous metastatic colorectal cancer presenting with liver‑only and lung‑only metastases
Efficacy of cetuximab‑based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta‑analysis
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment